Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early-and very early-stage hepatocellular carcinoma

Objective:To compare the safety of conventional transarterial chemoembolization(cTACE)vs drug-eluting bead TACE(DEB-TACE)in very early-and early-stage hepatocellular carcinoma(HCC).Methods:Data of patients with early-and very early-stage HCC treated with cTACE or DEB-TACE were evaluated retrospectively in this study.A total of 40 patients were included,20 treated with cTACE and 20 with DEB-TACE.The cTACE and DEB-TACE groups were comprised of 80%and 75%males,while there were 20%females in cTACE group and 25%in Deb-TACE group respectively.The mean age of patients in cTACE group was 57.43+5.6 years,while it was 56.4+5.5 years in DEB-TACE group.All patients had liver status of Child–Pugh Class A and a score≤7 in Child-Pugh class type B in very early-(stage 0)or early-phase(stage A)stages according to the Barcelona Clinic Liver Cancer(BCLC)system.Results:The Child-Pugh class degradation in the cTACE group was slightly higher than that in the DEB-TACE group.Serious complications like peritumoral parenchymal ischemia were observed in 4 patients in the cTACE group and 5 in the DEB-TACE group.Localized bile duct dilation was seen in 2 patients in the cTACE group and 6 in the DEB-TACE group.No significant variation in serious complications between the two groups was established in localized bile duct dilatation.Other minor complications noted were liver failure,liver abscess,liver infarction,acute cholecystitis,biliary tree necrosis,and mortality.Further,no substantial variation in tumor response between the groups was reported immediately and 1-year post-procedural assessment.Conversion rate to other treatment modalities such as surgical resection,radiofrequency ablation(RFA),or swap between cTACE and DEB-TACE was substantially higher in the DEB-TACE group(40%)than in the cTACE group(10%)at the 1-year completion period of the study.Conclusion:In terms of tumor response,the DEB-TACE group showed a better response,to some extent,as an initial therapy for HCC in the early stages as compared to the cTACE group,and DEB-TACE also exhibited better clinical efficacy in patients with HCC.